Evidence map›Paper›PMID 41254987›Full record

ArticleBiotechnology and bioengineering2026

AAV Assembled Capsids Are Produced in Cells Blocked From Cell Cycle Progression.

Alaka Mullick, Audrey Morasse, Melanie Leclerc, Ziying Liu, Qing Yan Liu, Sonia Leclerc, Milica Momcilovic, Annie Viau, Amine A Kamen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biotechnology and bioengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alaka MullickHuman Health Therapeutics, National Research Council of Canada, Montreal, Quebec, Canada.ORCID 0000-0001-8235-0175
Audrey MorasseHuman Health Therapeutics, National Research Council of Canada, Montreal, Quebec, Canada.
Melanie LeclercHuman Health Therapeutics, National Research Council of Canada, Montreal, Quebec, Canada.
Ziying LiuDigital Technologies Research Centre, National Research Council of Canada, Ottawa, Ontario, Canada.
Qing Yan LiuHuman Health Therapeutics, National Research Council of Canada, Montreal, Quebec, Canada.
Sonia LeclercHuman Health Therapeutics, National Research Council of Canada, Montreal, Quebec, Canada.
Milica MomcilovicDepartment of Bioengineering, McGill University, Montreal, Quebec, Canada.
Annie ViauHuman Health Therapeutics, National Research Council of Canada, Montreal, Quebec, Canada.
Amine A KamenDepartment of Bioengineering, McGill University, Montreal, Quebec, Canada.ORCID 0000-0001-9110-8815

Funding

This work was funded by the National Research Council Canada Disruptive Technology Solutions Cell and Gene Therapy challenge program. The NRC publication number is 53854.
6 · The paper itself

Abstract

Adeno-associated virus (AAV) is a promising delivery system for gene therapy. However, current manufacturing of AAV suffers from very low yields compared to other biotherapeutics. The AAV dose per patient ranges between 10

Indexed as

CapsidCell CycleDependovirusHEK293 CellsHumansAAVadeno‐associated viruscell cycleE1ARNA‐seq

Identifiers

PMID41254987
PMCPMC12779224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.